Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care

At Plus Therapeutics, our mission is clear: to address some of the toughest challenges in oncology by improving the efficacy, precision, and convenience of modern radiotherapeutic treatments.

We are pioneering a new era in radiotherapy, with the ultimate goal of establishing an innovative treatment platform that could one day become a global standard of care for cancer patients—especially those battling hard-to-treat tumors.

In a recent video interview, our President and CEO, Dr. Marc Hedrick, shares insights into our vision, scientific strategy, and the passionate team behind our advancements. Watch the interview to hear directly from Dr. Hedrick on how we’re working to transform the future of cancer care.

Watch the full interview here: https://lnkd.in/gjp7ADPG

From the lab to the clinic, Plus Therapeutics is committed to accelerating innovation in targeted radiotherapeutics, especially for central nervous system (CNS) cancers such as glioblastoma and leptomeningeal metastases.

To explore more about our pipeline, trials, and scientific approach, visit our website at www.plustherapeutics.com.

#Radiotherapeutics #Radiotherapy #Oncology #CancerResearch #CancerTreatment #TargetedTherapy #Glioblastoma #LeptomeningealMetastases #CNSCancer #PrecisionMedicine #InnovativeTherapies #ClinicalTrials #PSTV #PlusTherapeutics